Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Qilu’s first Avastin biosimilar Ankada needs strong commercialization strategy in China, says GlobalData

China-based Qilu Pharmaceutical received approval in December 2019 for QL-1101 under the trade name Ankada, a biosimilar to Avastin (bevacizumab), to treat advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Being the first approved Avastin biosimilar in China, Ankada will have the first-mover advantage, however its success will depend on a strong […]
Read more

Uncertain regulatory environment affecting growth and investments in India’s e-pharmacy sector, says GlobalData

Lack of progressive and proactive e-pharmacy regulatory framework is impacting the overall growth potential and future investments in the Indian e-pharmacy sector, says GlobalData, a leading data and analytics company.  In a bid to prohibit the unauthorized sale of medicines by certain e-pharmacies, the Drug Controller General of India (DCGI) ordered all states and union […]
Read more

Partnerships in the augmented and virtual reality space reflect growing interest in healthcare applications

In recent years, an increasing number of partnerships have been forged between large technology companies, start-ups developing healthcare-specific applications, hospitals, and research centers in the virtual reality (VR)/augmented reality (AR) space due to increasing healthcare expenditure and the need for cutting-edge technologies to aid the development of novel therapies and diagnostics, according to GlobalData, a […]
Read more

Vaccine developments will bolster interest and market growth in the infectious diseases space, says GlobalData

Looking to the horizon for 2020, Michael Breen, Associate Director of Infectious Diseases, and Philipp Rosenbaum, Infectious Diseases Analyst, at leading data and analytics company GlobalData, comment on the key trends and events shaping the vaccines space in 2020. Expansion into new patient segments and geographies Breen says: “Merck’s Gardasil franchise has proven to be […]
Read more

Incyte’s topical Jakafi draws long-term side-effect caution, says GlobalData

Following Incyte’s announcement about positive topline Phase III results for topical Jakafi (ruxolitinib) in the treatment of mild-to-moderate atopic dermatitis (AD); Reynald Castaneda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company, discusses his reporting: “While experts I interviewed prior to Incyte’s announcement were optimistic about the Phase III’s […]
Read more

Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData

As 2020 commences for the pharmaceutical industry, Fern Barkalow, PhD, Senior Director of Oncology and Hematology, as well as members of her analyst team at leading data and analytics company GlobalData comment on some of the key trends that will continue to influence clinical development in both solid tumors and hematological cancers in 2020, including […]
Read more

HIV first-in-class pipeline sees high levels of innovation that targets drug resistance and latency reversal

The human immunodeficiency virus (HIV) pipeline is robust, with 450 products in active development that display a high degree of novelty and diversity. Promisingly, there are 87 first-in-class products that act on a range of 50 molecular targets, which can broadly be classified as host or viral factors, indicating a high level of innovation in comparison with the marketed products, says GlobalData, a leading data and analytics company. The company’s recent report, ‘HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal’, reveals that the majority of the 10 highest-ranking targets have […]
Read more

China can use lessons they learned from SARS outbreak to tackle new Wuhan coronavirus, says GlobalData

Following the news that cases of people infected with the Wuhan coronavirus rose to more than 270 laboratory-confirmed cases and the virus may spread from human-to-human; Philipp Rosenbaum, Infectious Diseases Analyst at GlobalData, a leading data and analytics company, provides his view:  “China has experience with this kind of viral outbreak. The new coronavirus 2019-nCoV […]
Read more

Immuno-oncology and personalized medicine will continue to drive the pharmaceutical industry in 2020

Nearly three quarters of global industry stakeholders identified immuno-oncology (I-O) or personalized medicine as the most impactful trends that will shape the pharmaceutical sector in 2020, says GlobalData, a leading data and analytics company. Claire Herman, Global Director of Therapy Analysis and Epidemiology at GlobalData, comments: “For the second consecutive year, our survey found that […]
Read more

Biosimilars will contribute to cost-savings in US pharmaceutical industry in 2020

The pharmaceutical industry is mixed on the factors that will have the greatest positive impact on the industry in 2020, with patent expiry of biologics and vertical integration highlighted as some of the key areas of interest, says leading data and analytics company, GlobalData. According to the company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2020’, about 20% of survey respondents respectively identified patent expiry of biologics and vertical integration […]
Read more

Pricing and reimbursement concern to remain the leading impediment to industry growth in 2020

In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a leading data and analytics company. The company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2020’, reveals that 49% of global industry survey respondents believe that […]
Read more
1 … 101 102 103 104 105 … 108